Neomercazole (Carbimazole)

Carbimazole is converted to methimazole after ingestion. Methimazole inhibits thyroid peroxidase, an enzyme essential for iodination of thyroglobulin and coupling reactions that produce T4 and T3 hormones. By blocking these steps, the drug reduces the amount of active thyroid hormone released into circulation.

The dosage of Neomercazole is individualized by the prescribing clinician based on the severity of thyroid over‑activity, patient weight, age, and laboratory results. Only a qualified healthcare professional should determine the appropriate dose and titration schedule.

Carbimazole is classified as pregnancy category D, indicating potential risk to the fetus and should only be used if the benefits outweigh the risks. It is not recommended for breastfeeding mothers because it can be excreted in breast milk and may affect the infant.

To request Neomercazole, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neomercazole (carbimazole) is a pro‑drug of methimazole and is generally considered equivalent in efficacy to methimazole tablets. Compared with propylthiouracil, carbimazole has a lower risk of severe liver toxicity but shares similar risks of agranulocytosis, making it a preferred first‑line option in many regions.

Neomercazole tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect them from moisture, excessive heat and direct sunlight to maintain stability and potency throughout the shelf life.

Neomercazole is taken orally, usually once daily or as directed by the prescriber. Tablets should be swallowed whole with water and can be taken with or without food, unless the healthcare provider advises otherwise.

The most serious adverse reactions include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe liver injury. Patients should promptly report signs of infection such as fever or sore throat, and any symptoms of jaundice or abdominal pain.

Neomercazole is contraindicated in patients with known hypersensitivity to carbimazole or methimazole, those with severe liver disease, and pregnant or breastfeeding women unless the therapeutic benefit justifies the risk. It should also be avoided in individuals with pre‑existing agranulocytosis.